TURKU, FI / ACCESS Newswire / May 30, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Phase I study shows promising clinical activity and tolerability of bexmarilimab plus standard-of-care in ...

Auron has dosed the first subject in the Phase I trial of AUTX-703, targeting individuals with advanced haematologic ...

AUTX-703 is a novel, first-in-class, orally available KAT2A/B degrader discovered and developed by Auron using its AURIGIN™ Platform. The Company has previously presented preclinical data ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

During a live event, Gary J. Schiller, MD, reviewed the diagnostics and characteristics of blastic plasmacytoid dendritic ...

French biotech ImCheck Therapeutics is preparing to showcase encouraging interim results for its investigational monoclonal ...

Doctors highlighted the need for a comprehensive national strategy to tackle AML and the need for recognising the ...

TURKU, FI / ACCESS Newswire / May 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New preclinical data published in Scientific Reports confirms CLEVER-1 inhibition by Bexmarilimab increases ...

Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value ...

Don't dismiss persistent fatigue and bruising. These 11 warning signs could indicate acute myelogenous leukemia hiding in ...